ARS Pharma insider plans $368K stock sale
ARS Pharmaceuticals, Inc. (SPRY) is named as the issuer in a Form 144 notice filed on behalf of Sarina Tanimoto, covering proposed sales of company common stock under Rule 144.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ARS Pharmaceuticals, Inc. (SPRY) is named as the issuer in a Form 144 notice filed on behalf of Sarina Tanimoto, covering proposed sales of company common stock under Rule 144. The filing lists 63,289 shares of common stock to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $368,099.12, and an SEC file number of 001-39756. The notice also reports that during the prior three months Sarina Tanimoto sold 25,000 shares of common stock for $147,970.00 on 08/20/2026, 25,000 shares for $161,170.00 on 08/19/2026, and 49,401 shares for $311,191.72 on 08/18/2026. The proposed new sale is associated with a stock option exercise for cash as of 08/31/2026.
Key Figures
Key Terms
Rule 144 regulatory
Form 144 regulatory
Stock Option Exercise financial
Securities To Be Sold financial
Securities Sold During The Past 3 Months financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 144 filing for SPRY by Sarina Tanimoto disclose?
Which broker is named in the SPRY Form 144 for the proposed sale?
What prior SPRY stock sales by Sarina Tanimoto are reported in the last three months?
What is the relationship between the proposed SPRY sale and stock options?
AI-generated analysis. How Rhea-AI works. Not financial advice.